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Abstract The inhibitor of Q-glutamyl transpeptidase (Q-GT)
acivicin modulates cellular responses including growth, myeloid
maturation and apoptosis. Whether these effects result from the
inhibition of Q-GT enzyme activity remains unclear. We
compared the cellular effects of acivicin against a more potent
and specific inhibitor of Q-GT (L-2-amino-4-boronobutanoic acid
(L-ABBA)) in Q-GT-negative (B lymphoblastoid Ramos) and Q-
GT-positive (myelomonocytic HL-60, Q-GT-transfected Ramos)
cell lines. Under non-oxidative stress conditions, acivicin-induced
cell growth arrest, apoptosis and macrophage maturation
occurred independent of Q-GT while L-ABBA did not influence
any of these processes. Acivicin triggered tyrosine phosphoryla-
tion and increased nuclear factor UB activity. Further insight into
the role of Q-GT in cellular processes is needed. ß 2001 Fed-
eration of European Biochemical Societies. Published by Else-
vier Science B.V. All rights reserved.
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1. Introduction
Cell surface peptidases (ectopeptidases) are transmembrane
enzymes present in a wide variety of tissues and cell types [1].
Dysregulated expression of some of them in human diseases
triggers research on their value as disease markers and on
their role in pathophysiology [1]. In vitro and in vivo use of
speci¢c inhibitors of ectopeptidases has revealed that some of
these enzymes may in£uence major cell functions such as met-
abolic regulation, growth, apoptosis, and motility [1,2]. Q-glu-
tamyl transpeptidase (Q-GT) (EC 2.3.2.2; CD224) is a wide-
spread ectopeptidase that catalyzes the transfer of the
Q-glutamyl moiety of Q-glutamyl peptides to other amino acid
and peptide acceptors as well as the hydrolytic cleavage of the
Q-glutamyl group of donor peptides [3]. Oxidative stress due to
elevated amounts of reactive oxygen species (ROS) can lead to
damage or destruction of cellular macromolecules such as
lipids, proteins, and nucleic acids. Among enzymatic antiox-
idants capable to prevent ROS formation or scavenge radical
species, Q-GT in vivo counteracts oxidative stress by breaking
down extracellular glutathione and making its component
amino acids available to the cells [4]. In vitro, cell surface
Q-GT protects Ramos B cells from oxidation-induced cell death
[5].
Acivicin is an irreversible inhibitor of Q-GT commonly used
to study its action. Acivicin interacts with the enzyme close to
the site at which Q-glutamylation occurs [6]. Acivicin blocks
cell proliferation in various cell types including leukocytes,
lung, colon, breast, renal and melanoma cells [1,2]. In human
myeloid cell lines and blood monocytes, acivicin-mediated cell
growth arrest is associated with an induction of maturation
toward macrophages [1,2]. Growth arrest by acivicin also cor-
relates with altered production of proin£ammatory cytokines
(interleukin-1L, TGF-L) [1,2]. Finally, acivicin may induce ap-
optosis of T and myeloid cell lines [1,7,8]. In phase I/II trials
of acivicin infusion in a large variety of solid tumors and
acute leukemias, tumor growth stabilization was associated
with myelosuppression, neurotoxicity and anemia [1,2]. There-
fore, limitations to the use of acivicin in vivo appear to in-
clude the toxicity and the low speci¢city of acivicin which is
known to inhibit several glutamine-dependent amidotransfer-
ases and enzymes involved in purine and pyrimidine biosyn-
thesis [9]. Therefore, new information on the functions of
Q-GT may help unravel the physiological role of this ectoen-
zyme.
Recently, a potent and selective Q-GT inhibitor, L-2-amino-
4-boronobutanoic acid (L-ABBA) [10], was described. In the
present study, we used acivicin, L-ABBA and a cell system in
which the parental Q-GT-negative B lymphoblastoid Ramos
cell line was stably transfected with human Q-GT cDNA [11]
to investigate the role of Q-GT in cell activation and apoptosis.
We report here that in the absence of oxidative stress, certain
e¡ects induced by acivicin in B and myeloid lineage cells
(growth, maturation and apoptosis) are independent of
Q-GT expression.
2. Materials and methods
2.1. Reagents
L-Q-Glutamyl-para-nitroaniline (Q-Glu-pNA), glycylglycine
(GlyGly), acivicin ((KS,5S)-K-amino-3-chloro-4,5-dihydro-5-isoxazole-
acetic acid), bisindolylmaleimide, genistein, tyrphostin 25, ortho-vana-
date, wortmannin and 1-oleyl-sn-glycero-3-phosphate were provided
by Sigma Chemical Co. (St. Louis, MO, USA). L-ABBA was charac-
terized previously [10]. Phycoerythrin (PE)-conjugated Apo 2.7
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(2.7A6A3, mIgG1), PE-conjugated mouse IgG1, goat F(abP)2 frag-
ment anti-mouse £uorescein-conjugated Ig, monoclonal antibodies
(mAbs) speci¢c for CD11b (SP2, mIgG1), CD71 (YDJ.1.2.2,
mIgG1) and control isotypes were obtained from Coulter Immuno-
tech (Coultronics, France).
2.2. Cell lines and culture conditions
HL-60, Ramos and Q-GT-transfected Ramos cell lines [11] were
maintained in RPMI 1640 medium supplemented with 10% heat-in-
activated fetal calf serum (FCS; Gibco, Parsley, UK, LPS levels 6 0.1
ng/ml), 2 mM L-glutamine, 1 mM sodium pyruvate and 40 Wg/ml
gentamicin (Flow Laboratories, Rockwell, MD, USA) in a 5% CO2
humidi¢ed atmosphere at 37‡C. Q-GT-transfected Ramos cell line was
selected in culture medium with 0.25 mg/ml G418 antibiotic [10].
Thereafter, cells (1^10U105 cells/ml) were resuspended in fresh me-
dium containing FCS and 10 mM HEPES in tissue culture £asks, and
were grown for various periods of time, in the absence or in the
presence of di¡erent concentrations of acivicin and L-ABBA. After
various periods of incubation, cells were collected, washed twice,
counted with a Coulter Counter ZM equipped with a Coultronic
256 channelizer and their viability was determined by trypan blue
exclusion.
2.3. Assessment of cell proliferation and di¡erentiation
Cell number was assessed using a Coulter Counter ZM equipped
with a Coultronic 256 channelizer. To quantify DNA synthesis, the
cultures (100 Wl) were pulsed for an additional 18 h with 1 WCi/well
[3H]methylthymidine (NEN-DuPont de Nemours, Paris, France).
After cell harvesting, incorporated radioactivity was measured using
a L-scintillation counter. HL-60 cell maturation was determined ac-
cording to morphologic and phenotypic changes. For cell morphol-
ogy, cells were resuspended in phosphate-bu¡ered saline (4U104 cells/
100 Wl) and centrifuged at 50Ug for 5 min in a cytospin apparatus.
Slides were stained with the Hemacolor kit from Merck and subse-
quent light microscope examination.
2.4. Flow cytometry analysis
Cells were immunostained as previously described [12]. Analysis
was performed on a FACS £ow cytometer analyzer (Becton Dick-
inson, Mountain View, CA, USA); 10 000 events were recorded and
analyzed using the Lysys software (Becton Dickinson). Fluorescence
data were expressed in relative £uorescence intensity (%) and antigen
relative density per cell was obtained by substracting the peak channel
number of the negative control from the peak channel number of the
corresponding experimental sample. Induction of maturation was as-
sayed by measuring CD11b and CD71 antigens [12]. Apoptosis was
assessed by measuring the appearance of Apo 2.7 antigen, a mito-
chondrial membrane protein lately exposed on the surface of cells
undergoing programmed cell death [13].
2.5. Q-GT assay
Q-GT activity at the surface of intact cells was assayed as previously
described [14] using Q-Glu-pNA as a substrate of Q-GT hydrolytic
activity and GlyGly as glutamate acceptor for the transpeptidation
reaction. Results were expressed as nmol of pNA formed per 105 cells
at 37‡C.
3. Results
3.1. E¡ects of acivicin and L-ABBA on Q-GT activity at the
surface of HL-60 and Q-GT-transfected Ramos cells
As shown in Fig. 1, HL-60 and Q-GT-transfected Ramos
cells expressed a Q-GT activity associated with the surface of
cells (Fig. 1A,B). L-ABBA and acivicin induced a dose-depen-
dent inhibitory e¡ect on Q-GT activity (Fig. 1). On both cell
lines, L-ABBA was found to be a more potent inhibitor of
Q-GT (with IC50 30 nM) than acivicin (with IC50 30 WM). Under
identical conditions, the IC50 values for the inhibition of pu-
ri¢ed Q-GT were 45 WM for acivicin and 50 nM for L-ABBA.
No Q-Glu-pNA hydrolyzing activity was detected at the sur-
face of the parental Ramos cell line (data not shown).
3.2. Divergent e¡ects of acivicin and L-ABBA on HL-60 and
Ramos cell proliferation
HL-60, parental and Q-GT-transfected Ramos cells were
cultured for 3 days in the presence of a range of concentra-
tions (from 1037 to 1034 M) of acivicin or L-ABBA. At day 3,
the dose-dependent growth inhibition of two Q-GT-positive
cell lines by acivicin (Fig. 2A) was accompanied by an inhi-
bition of their surface Q-GT activity (Fig. 2B). Acivicin also
induced a growth arrest in Q-GT-negative Ramos cells (Fig.
2A). The inhibitory growth e¡ect of acivicin was already ob-
served after 1 day of treatment in the same range of concen-
trations (data not shown). By contrast, L-ABBA, which was a
more potent inhibitor of cell surface Q-GT activity than acivi-
cin (Fig. 2D), did not a¡ect the growth of any cell line (Fig.
2C).
3.3. Acivicin, but not L-ABBA, induces macrophage maturation
On day 3 of culture, treatment of HL-60 cells with acivicin
(1035 M) resulted in induction of macrophage maturation
shown by increased CD11b and CD71 densities (Fig. 3A)
and morphologic changes characteristic of macrophages
(Fig. 3B, compare a and b). L-ABBA at the same concentra-
tion neither a¡ected the levels of CD11b and CD71 nor cell
morphology when compared to untreated HL-60 cells (Fig. 3,
compare a and c).
3.4. Acivicin promotes apoptosis of Q-GT-negative and
Q-GT-positive cells
To assess whether acivicin and L-ABBA are capable of ei-
ther enhancing or down-regulating apoptosis, we measured
the appearance of Apo 2.7 antigen by means of £uorescence
£ow cytometry. HL-60, parental and transfected Q-GT Ramos
cells were cultured for 3 days in the absence or presence of
1035 M inhibitor. As shown in representative cytograms (Fig.
4A, control), Apo 2.7 antigen was expressed on less than 10%
of untreated cells. The levels of Apo 2.7 on L-ABBA-treated
Fig. 1. Inhibition of cell surface Q-GT activity on HL-60 and Q-GT-
transfected Ramos cells. Cells were incubated with Q-Glu-pNA and
GlyGly in the absence or presence of increasing concentrations
(1038^1034 M) of acivicin (b) or L-ABBA (a) for 60 min at 37‡C
as described in Section 2. A: HL-60 cells; B: Q-GT-transfected Ra-
mos cells.
FEBS 25448 12-11-01 Cyaan Magenta Geel Zwart
C. Antczak et al./FEBS Letters 508 (2001) 226^230 227
cells remained close to that of untreated cells (Fig. 4A, +L-
ABBA). In contrast, acivicin induced a marked increase of
Apo 2.7 on HL-60 and Q-GT-transfected Ramos cells but
also on Q-GT-negative Ramos cells (Fig. 4A, +acivicin). Aci-
vicin consistently induced apoptosis at doses of 1035 M for
HL-60 cells (Fig. 4B) as well as for Ramos cells (data not
shown).
3.5. Inhibitors of tyrosine phosphorylation inhibit acivicin-
mediated growth arrest in HL-60 cells
In an attempt to determine which signaling pathways were
involved in the HL-60 growth arrest mediated by acivicin
(5U1036 M), we examined the e¡ects of various agents
known to alter intracellular signaling (Table 1). Pretreatment
of HL-60 cells with the two tyrosine phosphorylation inhib-
itors genistein or tyrphostin 25 reversed the acivicin-mediated
growth arrest (Table 1). In contrast, the other agents were
without e¡ect (Table 1). However genistein did not protect
HL-60 cells from apoptosis induced by doses of acivicin of
1035 M (data not shown).
4. Discussion
Q-GT is an ectoenzyme expressed in di¡erent cell types in-
cluding hematopoietic cells. Thus far, knowledge about the
involvement of Q-GT in cell physiology comes mainly from
the inhibition of its catalytic activity by acivicin [1,2]. Acivicin
blocks cell proliferation in various cell types including leuko-
cytes, lung, colon, breast, renal, and melanoma cells [1,2]. The
inhibitor-mediated cell growth arrest is associated with an
induction of maturation of myeloid precursors toward macro-
phages, and apoptosis of T and myeloid cell lines [1,2]. Aci-
vicin inhibits several glutamine-dependent amidotransferases
and enzymes involved in purine and pyrimidine biosynthesis.
In the present study, we sought to reevaluate the acivicin-
associated apoptosis and the antiproliferative/di¡erentiative
action of acivicin. Using Q-GT-negative (Ramos) and Q-GT-
positive (HL-60 and Q-GT-transfected Ramos) cell lines as
well as a more potent and selective inhibitor of Q-GT (L-
ABBA) recently developed [10], we report here that, in the
Fig. 2. Dose^response curves of the e¡ect of acivicin or L-ABBA on cell growth and cell surface Q-GT activity. HL-60, parental and Q-GT-
transfected Ramos cells were cultured in the absence or presence of increasing concentrations of acivicin (A and B) or L-ABBA (C and D)
(from 1037 to 1034 M). At 3 days of incubation, cells were assayed for cell growth (A and C) and cell surface Q-GT (B and D) as described in
Section 2. Cell proliferation as determined by [3H]thymidine incorporation is expressed as the percentage of growth of untreated cells, each de-
termination representing the mean of triplicates. Q-GT activity is expressed as the percentage of activity of unstimulated cells. E¡ects of acivicin
(black symbols) or L-ABBA (white symbols) were assayed on HL-60 (b, a), parental Ramos (R, O) or Q-GT-transfected Ramos (F, E) cell
lines.
Fig. 3. E¡ects of acivicin and L-ABBA on morphologic and pheno-
typic changes of HL-60 cells. HL-60 cells were cultured in the ab-
sence or presence of acivicin or L-ABBA (1035 M) for 3 days. A:
Cells were assayed for expression and relative densities of CD11b
and CD71. B: Light microscopy morphology of unstimulated cells
(a) or cells exposed to acivicin (b) or to L-ABBA (c). Hematocolor
staining. Scale bar, 10 WM.
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absence of oxidative stress, the induction of growth arrest,
di¡erentiation and apoptosis in target cells by acivicin is not
mediated through inhibition of Q-GT.
The boronate compound L-ABBA is a potent inhibitor of
puri¢ed Q-GT [10] designed as a speci¢c transition state analog
of the natural substrate. When the inhibitory potency of aci-
vicin and L-ABBA on HL-60 and Q-GT-transfected Ramos
Q-GT surface activity was investigated, we observed that
L-ABBA was a stronger inhibitor (IC50 30 nM) than acivicin
(IC50 30 WM). In the concentration range of 1037^1034 M,
L-ABBA did not exhibit any growth-inhibiting properties on
Q-GT-positive as well as Q-GT-negative cell lines. In contrast,
acivicin not only inhibited growth of Q-GT-positive cells as
previously shown [1,2] but also the Q-GT-negative Ramos
cell line.
Comparative experiments with L-ABBA showed that, in
addition to cell proliferation, acivicin also a¡ected myeloid
di¡erentiation and apoptosis independently of its inhibition
of Q-GT. The Q-GT-independent e¡ect of acivicin on apoptosis
has recently been observed in V79 Chinese hamster cells trans-
fected with human Q-GT [15]. The molecular mechanisms be-
hind all forms of acivicin-induced growth arrest/apoptosis are
not known. Acivicin causes cell cycle arrest due to the inhibi-
tion of de novo purine and pyrimidine synthesis. Culture of
acivicin-treated cells in nucleoside-supplemented medium by-
passes this block in DNA synthesis (D. Karp, unpublished
data). In Ramos cells transfected with Q-GT cDNA, short-
term incubation with acivicin (1035 M) under conditions of
oxidative stress induces apoptosis that can be reversed with
thiol supplementation [5]. This is consistent with the role that
Q-GT plays in the recapture of cysteine from extracellular
glutathione. Other transformed cells are not as sensitive to
oxidative stress as Ramos (D. Karp, unpublished data).
Induction and inhibition of growth arrest/apoptosis are
both associated with signaling through protein phosphoryla-
tion [16^19]. Protein kinase C (PKC) and mitogen-activated
protein kinases (MAPKs) (extracellular-regulated kinase
(ERK), c-Jun N-terminal kinase and p38) are implicated in
the regulation of many cellular processes [16^19]. There is
evidence that tyrosine phosphorylation steps are involved in
ectopeptidase signaling [1,20^26]. CD26/dipeptidyl peptidase
IV inhibitors activate MAPK-p38 and inhibit MEK1 and
ERK1/2 in CD3 antibody-mediated activated T cells
[1,20,23,25]. Intracellular calcium £ux and the MAPK phos-
phorylation are implicated in the activation of monocytes and
T cells through CD13/aminopeptidase N (APN) [1,21,22,24^
26]. Monocytic-induced di¡erentiation of HL-60 cells is asso-
ciated with changes in the patterns of protein phosphorylation
[27]. Here, we provided evidence that the acivicin-induced
growth arrest signaling pathway in HL-60 cells involves tyro-
sine phosphorylation. Moreover, cellular stimulation with aci-
vicin coincided with a higher degree of nuclear factor UB (NF-
UB) activation (data not shown). NF-UB plays a critical role in
proliferation and cell survival and is stimulated by a variety of
agents including tumor necrosis factor-K (TNF-K) [28]. How-
ever, untreated as well as acivicin-treated Ramos and HL-60
cells produced no detectable amounts of TNF-K (data not
Fig. 4. E¡ects of acivicin and L-ABBA on the levels of apoptosis in
HL-60, parental and Q-GT-transfected Ramos cells. A: HL-60, pa-
rental and Q-GT-transfected Ramos cells cultured for 3 days in the
absence or presence of acivicin or L-ABBA (1035 M) were assayed
for expression of Apo 2.7 as described in Section 2. FACS pro¢les
from a representative experiment are shown. The dotted histograms
represent background £uorescence obtained with the isotype control
and the solid histograms represent speci¢c £uorescence obtained
with Apo 2.7 mAb. B: HL-60 cells cultured for 3 days in the ab-
sence or presence of increasing concentrations of acivicin (5U1036^
1034 M) were assayed for apoptosis (n = 8 for control, n = 4 for
5U1036 M, n = 3 for 1035 and 5U1035 M, n = 2 for 1034 M).
Table 1
Acivicin-mediated growth arrest response of HL-60 cells upon treatment with agents of signaling pathways
Pretreatment E¡ect Residual cell growth (%)
Exp 1 Exp 2 Exp 3
None control 18 þ 3 8 þ 1 24 þ 2
Bisindolylmaleimide PKC inhibitor 16 þ 3
1-Oleyl-sn-glycero-3-phosphate activator of G proteins 16 þ 3 18 þ 1
Vanadate tyrosinephosphatase inhibitor 17 þ 1
Wortmannin phosphatidylinositol-3-kinase inhibitor 23 þ 2
Tyrphostin 25 tyrosine kinase inhibitor 74 þ 13
Genistein tyrosine kinase inhibitor 102 þ 15 97 þ 6 77 þ 5
Cells were pretreated with di¡erent agents (bisindolylmaleimide and 1-oleyl-sn-glycero-3-phosphate 4 WM; wortmannin 5 WM; genistein 7.5 WM;
tyrphostin 25 and vanadate 10 WM) for 1 day prior to exposure to acivicin (5U1036 M). In the absence of acivicin, the agents were without
any toxic e¡ect on growth. After 2 days, cell proliferation was determined by [3H]thymidine incorporation. Results are expressed as the percent-
age of growth of untreated cells ( þ S.D., n = 3).
FEBS 25448 12-11-01 Cyaan Magenta Geel Zwart
C. Antczak et al./FEBS Letters 508 (2001) 226^230 229
shown) excluding its participation in the e¡ects produced by
acivicin. Details of the mechanisms of acivicin-induced cell
activation are currently under investigation.
In conclusion, growth inhibition, monocyte maturation and
apoptosis induced by acivicin can be mediated by mechanisms
other than inhibition of Q-GT. Other investigators have re-
cently shown that the antiproliferative e¡ects of actinonin,
an inhibitor of the ectopeptidase CD13/APN involved in tu-
mor invasion [24], are independent of CD13/APN [29].
L-ABBA was a potent inhibitor of Q-GT, yet did not cause
growth arrest or apoptosis in our cellular models. Thus,
Q-GT activity is dispensable for cells cultured with typical
levels of sulfur-containing amino acids for the synthesis of
glutathione, and without additional oxidative stress to deplete
intracellular glutathione stores.
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